Craneware was trading around 1,058p on 11 November, up 2.72%. Attention remains centred on its healthcare software platform, its recent annual reporting cycle and the opportunity created by ongoing US hospital cost and revenue-management pressures. That makes LSE:CRW relevant today because investors are not …
NIOX traded around 63.6p on 11 November, down 1.24%, after a period of volatile trading. The company remains focused on respiratory diagnostics, with investor attention centred onDemandfor its FeNO testing platform and the durability of recurring revenues. That makes LSE:NIOX relevant today because investors …
The company-specific item for the session was a broker move. Citigroup cut its price target on GSK (LSE:GSK) to 2,050p from 2,100p while keeping its 'neutral' rating. That is a modest reduction, and the rating was unchanged, but it is the only specific development …
That leaves a practical question for holders: which steps remain, and what timetable has the company given? The answer rests on the original terms announced on 25 June 2026 and the update issued after theShareholdermeetings on 12 August.
Tristel, based in Cambridgeshire, makes chlorine dioxide disinfectants used mainly to decontaminate reusable medical instruments such as ultrasound probes and endoscopes. According to the 9 November announcement it employs about 280 people across 16 subsidiaries and sells into more than 40 countries.
The company saidRevenuefor the six months to 30 September was expected to be about £96m, around 60% higher than a year earlier, driven by PAM and by organic growth. NetDebtat 30 September was £70.4m. Trading was in line with expectations, and the board expected …
LSE:UPR distributes medicines and medical devices and provides outsourced services to pharmaceutical manufacturers. It reports through three divisions: Uniphar Pharma, which includes global sourcing of hard-to-find medicines; Uniphar Medtech, which sells specialist devices to hospitals; andSupplyChain and Retail, which serves pharmacies in Ireland and …
• The immediate reason for attention is Oxford BioMedica has a fresh near-term visibility catalyst after announcing that its chief executive is due to present at a major healthcare conference in London. Its September interim results highlighted continuedRevenuegrowth, a record number of new client …
• Coiled Therapeutics is in focus around clinical development of AO-252 and the potential for data-driven milestones as its precision-oncology platform advances.
• A fresh update on the ECOVAXXIN MG marketing-authorisation application and the company’s capital-markets programme make Eco Animal Health a clear healthcare focus today.